再生醫學市場－全球產業規模、佔有率、趨勢、機會和預測（按療法、材料、應用、最終用戶、地區和競爭細分，2020-2030 年）

2024年全球再生醫學市場規模達146.7億美元，預計在預測期內將顯著成長，到2030年複合年成長率將達到9.45%。再生醫學是一門新興學科，專注於修復或再生受損的人體器官或組織。這種治療方法利用幹細胞來恢復無法自我療癒的組織和器官的功能。

例如，根據美國癌症協會的估計，2023 年美國報告的新癌症病例約為 1,958,310 例，癌症相關死亡人數約為 609,820 人，這推動了市場的成長。科學家預計，這種療法將使器官和組織能夠在實驗室中生長，然後可以安全地植入人體內。再生醫學的需求正在迅速成長，因為它的個人化治療方法與傳統治療方法相比，可以更有效地管理病情。再生醫學涵蓋一系列醫療技術，包括人造器官、細胞療法和組織工程。組織工程和生物材料採用植入體內的支架來促進新組織的形成。這些支架吸引幹細胞，促進具有所需形狀的組織發育。細胞療法利用來自牙髓、脂肪、骨骼肌、血液、骨髓和其他來源的幹細胞來修復體內受損的組織。醫療設備和人造器官為體內衰竭的器官提供支持。

關鍵市場促進因素

增加研發活動投資

主要市場挑戰

缺乏可靠的細胞和基因治療載體生產

主要市場趨勢

新興經濟體潛力增強

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球再生醫學市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依療法（幹細胞療法、基因療法、組織工程、小分子和生物製劑）
  • 依材料（合成材料、生物衍生材料、基因工程材料及藥品）
  • 依應用（心血管、腫瘤、肌肉骨骼、傷口癒合、眼科等）
  • 按最終用戶（醫院、專科中心、學術和研究機構）
  • 按地區
  • 按公司分類（2024）
• 市場地圖

第6章：北美再生醫學市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲再生醫學市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 德國
  • 英國
  • 義大利
  • 法國
  • 西班牙

第8章：亞太再生醫學市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：南美洲再生醫學市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第10章：中東與非洲再生醫學市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

第 13 章：全球再生醫學市場：SWOT 分析

第 14 章：競爭格局

• Stryker Corporation
• Athersys, Inc.
• Integra Lifesciences Corporation
• Isto Biologics (Isto Biologics Medical Systems, Inc.)
• Organogenesis Inc.
• CryoLife, Inc.
• Medtronic plc
• US Stem Cell, Inc.
• Zimmer Biomet Holdings, Inc.
• 3M Company

第 15 章：策略建議

第16章調查會社について,免責事項

Global Regenerative Medicine Market was valued at USD 14.67 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 9.45% through 2030F. Regenerative medicine is an emerging discipline that focuses on the replacement or regeneration of damaged human organs or tissues. This therapeutic approach utilizes stem cells to restore function to tissues and organs that are unable to heal themselves.

For instance, according to estimates from the American Cancer Society, approximately 1,958,310 new cancer cases and 609,820 cancer-related deaths were reported in the U.S. in 2023, driving growth in the market. Scientists anticipate that this therapy will enable the laboratory growth of organs and tissues, which can then be safely implanted into the human body. The demand for regenerative medicine is rapidly increasing due to its personalized treatment approach, which provides more effective management of conditions compared to conventional treatments. Regenerative medicine encompasses a range of medical techniques, including artificial organs, cellular therapies, and tissue engineering. Tissue engineering and biomaterials employ scaffolds that are implanted in the body to facilitate the formation of new tissue. These scaffolds attract stem cells, promoting the development of tissue with the desired shape. Cellular therapies utilize stem cells derived from dental pulp, fat, skeletal muscle, blood, bone marrow, and other sources to repair damaged tissues within the body. The medical devices and artificial organs offer support to failing organs within the body.

Key Market Drivers

Increasing Investments in R&D Activities

Increasing investments in research and development (R&D) activities have propelled market growth by driving innovative product launches. This surge in investments has led to comprehensive R&D initiatives, with numerous start-up companies receiving funding for the development of novel therapies and products. Consequently, this has facilitated significant collaborations, mergers, and partnerships aimed at maximizing the mutual benefits of R&D activities. In June 2022, Galapagos, a Belgian biotech company, announced its acquisition of Cell Point and Abound Bib. This strategic move aims to expedite the development and commercialization of next-generation cell therapies. With the integration of Cell Point and Abound Bio, Galapagos will gain access to innovative, scalable, decentralized, and automated point-of-care cell therapy supply models, as well as a cutting-edge fully human antibody-based therapeutics platform. Together, these advancements position Galapagos as a fully integrated biopharmaceutical company with the potential to disrupt the CAR-T treatment paradigm. Apart from private entities, various governments and government-funded research institutes are actively investing in this industry to introduce effective treatment options for chronic diseases like cancer, Parkinson's disease, diabetes, renal diseases, cardiovascular diseases, and others. In January 2022, the Royal College of Surgeons in Ireland secured USD 226,000 in funding from the European Commission for the development of antioxidant-ion substituted nanoparticles for osteoporotic bone treatment.

Key Market Challenges

Lack of Reliable Vector Production for Cell and Gene Therapy

Current methods of vector production often have limitations in terms of scalability. Producing enough high-quality vectors to meet the demands of clinical trials and potential commercialization can be challenging, especially for therapies with large patient populations. As regenerative medicine advances, the diversity of therapeutic approaches and vector types increases. Developing reliable vector production methods for various vectors, including adeno-associated viruses (AAVs) and lentiviruses, is crucial to accommodate this diversity.

Key Market Trends

Increase In Potential in Emerging Economies

Developing economies hold significant potential in the regenerative medicine market, driven by the rising prevalence of traumatic injuries and organ transplantations worldwide. Key industry players have strategically analyzed the opportunities in tissue engineering and regenerative medicine within these economies, leveraging various developmental strategies such as product launches, approvals, agreements, partnerships, and mergers. Despite ethical challenges arising from unfavorable norms, it is anticipated that developing economies will embrace tissue-engineering and regeneration technology.

Key Market Players

• Stryker Corporation
• Athersys, Inc.
• Integra Lifesciences Corporation
• Isto Biologics (Isto Biologics Medical Systems, Inc.)
• Organogenesis Inc.
• CryoLife, Inc.
• Medtronic plc
• U.S. Stem Cell, Inc.
• Zimmer Biomet Holdings, Inc.
• 3M Company

Report Scope:

In this report, the Global Regenerative Medicine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Regenerative Medicine Market, By Therapy:

• Stem Cell Therapy
• Gene Therapy
• Tissue Engineering
• Small Molecule & Biologic

Regenerative Medicine Market, By Material:

• Synthetic Material
• Biologically Derived Material
• Genetically Engineered Material
• Pharmaceuticals

Regenerative Medicine Market, By Application:

• Cardiovascular
• Oncology
• Musculoskeletal
• Wound Healing
• Ophthalmology
• Others

Regenerative Medicine Market, By End User:

• Hospitals
• Specialty Centres
• Academic & Research Institutes

Regenerative Medicine Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Regenerative Medicine Market.

Available Customizations:

Global Regenerative Medicine market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Regenerative Medicine Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Therapy (Stem Cell Therapy, Gene Therapy, Tissue Engineering, And Small Molecule & Biologic)
  • 5.2.2. By Material (Synthetic Material, Biologically Derived Material, Genetically Engineered Material, And Pharmaceuticals)
  • 5.2.3. By Application (Cardiovascular, Oncology, Musculoskeletal, Wound Healing, Ophthalmology, And Others)
  • 5.2.4. By End User (Hospitals, Specialty Centres, Academic & Research Institutes)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Regenerative Medicine Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapy
  • 6.2.2. By Material
  • 6.2.3. By Application
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Regenerative Medicine Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Therapy
      • 6.3.1.2.2. By Material
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Regenerative Medicine Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Therapy
      • 6.3.2.2.2. By Material
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Regenerative Medicine Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Therapy
      • 6.3.3.2.2. By Material
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End User

7. Europe Regenerative Medicine Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapy
  • 7.2.2. By Material
  • 7.2.3. By Application
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Regenerative Medicine Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapy
      • 7.3.1.2.2. By Material
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End User
  • 7.3.2. United Kingdom Regenerative Medicine Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapy
      • 7.3.2.2.2. By Material
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End User
  • 7.3.3. Italy Regenerative Medicine Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecasty
      • 7.3.3.2.1. By Therapy
      • 7.3.3.2.2. By Material
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End User
  • 7.3.4. France Regenerative Medicine Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Therapy
      • 7.3.4.2.2. By Material
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Regenerative Medicine Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Therapy
      • 7.3.5.2.2. By Material
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End User

8. Asia-Pacific Regenerative Medicine Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapy
  • 8.2.2. By Material
  • 8.2.3. By Application
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Regenerative Medicine Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapy
      • 8.3.1.2.2. By Material
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End User
  • 8.3.2. India Regenerative Medicine Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapy
      • 8.3.2.2.2. By Material
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Regenerative Medicine Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapy
      • 8.3.3.2.2. By Material
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Regenerative Medicine Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Therapy
      • 8.3.4.2.2. By Material
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Regenerative Medicine Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Therapy
      • 8.3.5.2.2. By Material
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End User

9. South America Regenerative Medicine Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapy
  • 9.2.2. By Material
  • 9.2.3. By Application
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Regenerative Medicine Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapy
      • 9.3.1.2.2. By Material
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina Regenerative Medicine Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapy
      • 9.3.2.2.2. By Material
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia Regenerative Medicine Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Therapy
      • 9.3.3.2.2. By Material
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End User

10. Middle East and Africa Regenerative Medicine Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Therapy
  • 10.2.2. By Material
  • 10.2.3. By Application
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Regenerative Medicine Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Therapy
      • 10.3.1.2.2. By Material
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia Regenerative Medicine Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Therapy
      • 10.3.2.2.2. By Material
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE Regenerative Medicine Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Therapy
      • 10.3.3.2.2. By Material
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

13. Global Regenerative Medicine Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Stryker Corporation
• 14.2. Athersys, Inc.
• 14.3. Integra Lifesciences Corporation
• 14.4. Isto Biologics (Isto Biologics Medical Systems, Inc.)
• 14.5. Organogenesis Inc.
• 14.6. CryoLife, Inc.
• 14.7. Medtronic plc
• 14.8. U.S. Stem Cell, Inc.
• 14.9. Zimmer Biomet Holdings, Inc.
• 14.10. 3M Company

15. Strategic Recommendations

16. About Us & Disclaimer